GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Argenica Therapeutics Ltd (ASX:AGN) » Definitions » Accounts Payable

Argenica Therapeutics (ASX:AGN) Accounts Payable : A$1.19 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Argenica Therapeutics Accounts Payable?

Argenica Therapeutics's Accounts Payable for the quarter that ended in Dec. 2023 was A$1.19 Mil.

Argenica Therapeutics's quarterly Accounts Payable declined from Dec. 2022 (A$1.30 Mil) to Jun. 2023 (A$1.14 Mil) but then increased from Jun. 2023 (A$1.14 Mil) to Dec. 2023 (A$1.19 Mil).

Argenica Therapeutics's annual Accounts Payable increased from Jun. 2021 (A$0.37 Mil) to Jun. 2022 (A$0.67 Mil) and increased from Jun. 2022 (A$0.67 Mil) to Jun. 2023 (A$1.14 Mil).


Argenica Therapeutics Accounts Payable Historical Data

The historical data trend for Argenica Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argenica Therapeutics Accounts Payable Chart

Argenica Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
Accounts Payable
0.37 0.67 1.14

Argenica Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Accounts Payable Get a 7-Day Free Trial 0.04 0.67 1.30 1.14 1.19

Argenica Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.


Argenica Therapeutics Accounts Payable Related Terms

Thank you for viewing the detailed overview of Argenica Therapeutics's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.


Argenica Therapeutics (ASX:AGN) Business Description

Traded in Other Exchanges
N/A
Address
117 Broadway, Unit 4, Nedlands, WA, AUS, 6009
Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.

Argenica Therapeutics (ASX:AGN) Headlines

No Headlines